The Roadmap
This roadmap page will be updated as certain milestones will be completed and new challenges will added.

Next Steps: Genomic Sequencing Lab

From conversations within our Discord, we have had several folks voice opinions on where the best way to focus our attention on going forward. We see 4 big areas to prioritise focus:
  • Onboarding more tests and genomic queries to exponentially improve the immediate benefits of the genomic sequencing vaults for end users. To do this, we need to hire bioinformaticians
  • Business development - Working with organisations such as Rare Disease Charities and National Sequencing Initiatives
  • Staying at the forefront of the DeFi landscape aka Hiring more Solidity Developers
  • Improving the auditability of getting files from the sequencers to the vaults.

Snapshot Voting on Proposals

The roadmap for the prioritisation of functionality can be influenced by the GenomesDAO community voting on proposals.
Proposals can be suggested and voted upon at: https://snapshot.org/#/genomesdao.eth

Key Milestones

1. Apply tokenomics across platform

We have spent the last 3 years working with bioinformaticians and encryption experts, both in the GenomesDAO team and AMD to ensure the most secure storage of your most personal data.
In executing our proofs of computation and allowing repeat consent using mobile blockchain wallets, that are already live on the appstore.
We now need to allow for our freshly minted $GENE token to be used throughout the platform. A reminder the token will be deflationary and a percentage will be burned every time a sequencing kit is bought using $GENE.

#4 - 10,000 Genomes is our AMD SEV-ES vaults

We have several ways to achieve this through B2B and B2C initiatives. We envision NFT projects that combine whole genome sequencing kits with generative art, as pionered by our Geneticats NFT project. We also expect to increase vault growth through partnership with governmental sequencing campaigns.
We also have partnerships with 2 national genome sequencing initiatives to power repeat consent of genomic queries across their citizen cohorts, and are expanding our business development efforts globally in 2022.

#5 - Brokerage of Data to pharma - aka - making passive income for our users

We have done our market research with pharmaceutical companies, who are the ones who told us that genomic querying will become interesting for them within the global general public at 10,000 genomes. This is why we have this short term target and this is when we will begin brokering queries of users data that they can accept payment for, or turn down.
We will also be working with our business development leads to allow pharmaceutical companies to bulk buy $GENE, our deflationary utility token, allowing them to make more queries for less money, locking up GENE token supply at the same time.

#6 - Launch of GenomesDAO secure Organisational Platform (Rare Disease Charities etc)

We at GenomesDAO aim to supercharge rare disease research and development and accelerate the process of bringing new therapies to those patients that need them most.
One rare disease may only affect a handful of people, whereas another may touch as many as 245,000. However, the majority of these patients are members and part of the patient groups of national and international rare disease organisations. These organisations vary in size and organisational complexity but all provide information, advice and support services to their rare disease patient group, and fund vital research into their condition. There are around 250 of these organisations throughout the UK, 830 in Europe and 280 in the US.

#7 - Expansion of Tests Available - Open API to 3rd Parties

An open system will benefit from the wisdom of others. If you build genomic sequencing query tests, you can monetise them on our platform, and we’d love to hear from you, whether it’s a fun test - or a medically assured healthcare cohort study.
Copy link
On this page
Next Steps: Genomic Sequencing Lab
Snapshot Voting on Proposals
Key Milestones
1. Apply tokenomics across platform
#4 - 10,000 Genomes is our AMD SEV-ES vaults
#5 - Brokerage of Data to pharma - aka - making passive income for our users
#6 - Launch of GenomesDAO secure Organisational Platform (Rare Disease Charities etc)
#7 - Expansion of Tests Available - Open API to 3rd Parties